Selective serotonin-reuptake inhibitor-induced movement disorders.
Identifieur interne : 001764 ( PubMed/Curation ); précédent : 001763; suivant : 001765Selective serotonin-reuptake inhibitor-induced movement disorders.
Auteurs : P E Gerber [Canada] ; L D LyndSource :
- The Annals of pharmacotherapy [ 1060-0280 ] ; 1998.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Serotonin Uptake Inhibitors.
- chemically induced : Bruxism, Dystonia, Parkinson Disease, Secondary.
- drug therapy : Depression.
- etiology : Akathisia, Drug-Induced, Dyskinesia, Drug-Induced.
- Female, Humans, Male.
Abstract
To compile and evaluate all available data suggesting an association between selective serotonin-reuptake inhibitor (SSRI) administration and the occurrence of movement disorders, and to characterize these reactions in terms of onset, duration, treatment and outcome, and potential predisposing factors.
DOI: 10.1345/aph.17302
PubMed: 9640489
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001764
Links to Exploration step
pubmed:9640489Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Selective serotonin-reuptake inhibitor-induced movement disorders.</title><author><name sortKey="Gerber, P E" sort="Gerber, P E" uniqKey="Gerber P" first="P E" last="Gerber">P E Gerber</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver</wicri:regionArea></affiliation></author><author><name sortKey="Lynd, L D" sort="Lynd, L D" uniqKey="Lynd L" first="L D" last="Lynd">L D Lynd</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:9640489</idno><idno type="pmid">9640489</idno><idno type="doi">10.1345/aph.17302</idno><idno type="wicri:Area/PubMed/Corpus">001764</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001764</idno><idno type="wicri:Area/PubMed/Curation">001764</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001764</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Selective serotonin-reuptake inhibitor-induced movement disorders.</title><author><name sortKey="Gerber, P E" sort="Gerber, P E" uniqKey="Gerber P" first="P E" last="Gerber">P E Gerber</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver</wicri:regionArea></affiliation></author><author><name sortKey="Lynd, L D" sort="Lynd, L D" uniqKey="Lynd L" first="L D" last="Lynd">L D Lynd</name></author></analytic><series><title level="j">The Annals of pharmacotherapy</title><idno type="ISSN">1060-0280</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Akathisia, Drug-Induced (etiology)</term><term>Bruxism (chemically induced)</term><term>Depression (drug therapy)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Dystonia (chemically induced)</term><term>Female</term><term>Humans</term><term>Male</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Serotonin Uptake Inhibitors (adverse effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Serotonin Uptake Inhibitors</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Bruxism</term><term>Dystonia</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depression</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Akathisia, Drug-Induced</term><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Male</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To compile and evaluate all available data suggesting an association between selective serotonin-reuptake inhibitor (SSRI) administration and the occurrence of movement disorders, and to characterize these reactions in terms of onset, duration, treatment and outcome, and potential predisposing factors.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9640489</PMID><DateCreated><Year>1998</Year><Month>09</Month><Day>24</Day></DateCreated><DateCompleted><Year>1998</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1060-0280</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>6</Issue><PubDate><Year>1998</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Annals of pharmacotherapy</Title><ISOAbbreviation>Ann Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Selective serotonin-reuptake inhibitor-induced movement disorders.</ArticleTitle><Pagination><MedlinePgn>692-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compile and evaluate all available data suggesting an association between selective serotonin-reuptake inhibitor (SSRI) administration and the occurrence of movement disorders, and to characterize these reactions in terms of onset, duration, treatment and outcome, and potential predisposing factors.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">Reports of movement disorders were identified by conducting a comprehensive literature search that included tertiary adverse drug reaction resources, MEDLINE, EmBASE, Biological Abstracts, Current Contents, Reactions, ClinAlert, and International Pharmaceutical Abstracts. In addition, reports were solicited from the Canadian proprietary manufacturers of SSRIs, and from the Therapeutic Products Program of Health Canada. Each case was then classified according to the description of the movement disorder, based on predefined diagnostic criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 127 published reports of SSRI-induced movement disorders were identified involving akathisia (n = 30), dystonia (19), dyskinesia (12), tardive dyskinesia (6), parkinsonism (25), and 15 cases of mixed disorders. Ten isolated cases of bruxism were identified. Ten additional reports could not be classified. Manufacturers of SSRIs provided 49 reports of akathisia, 44 of dystonia, 208 of dyskinesia, 76 of tardive dyskinesia, 516 of parkinsonism, and 60 of bruxism. Treatment strategies included discontinuation of the SSRI; dosage reduction; or the addition of a benzodiazepine, beta-blocker, or anticholinergic agent.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SSRI use appears to be associated with the development of movement disorders, as either a direct result of the drug or exacerbation of an underlying condition. Predisposing factors may include the use of neuroleptics, existing neurologic diagnoses, or preexisting movement disorders. Clinicians should be cognizant of the potential for these reactions, as prompt recognition and management is essential in preventing potentially significant patient morbidity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gerber</LastName><ForeName>P E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynd</LastName><ForeName>L D</ForeName><Initials>LD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Pharmacother</MedlineTA><NlmUniqueID>9203131</NlmUniqueID><ISSNLinking>1060-0280</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017109" MajorTopicYN="N">Akathisia, Drug-Induced</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002012" MajorTopicYN="N">Bruxism</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004421" MajorTopicYN="N">Dystonia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>51</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>6</Month><Day>26</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>6</Month><Day>26</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9640489</ArticleId><ArticleId IdType="doi">10.1345/aph.17302</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001764 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001764 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:9640489
|texte= Selective serotonin-reuptake inhibitor-induced movement disorders.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:9640489" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |